INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences
INVO Bioscience has announced a corporate name change to NAYA Biosciences Inc. and will begin trading under the new symbol 'NAYA' on October 22, 2024. This change follows the recent merger with NAYA Biosciences, completed on October 14th. The newly combined company will maintain its revenue-generating fertility business while expanding into oncology and autoimmune diseases.
CEO Steve Shum stated that the name change and new trading symbol better reflect their expanded corporate strategy. The company aims to combine scalable, profitable revenues from the fertility business with the potential of innovative therapeutics. Their hub-and-spoke model is designed to share resources and talent to accelerate the development of lean, agile subsidiaries.
INVO Bioscience ha annunciato un cambio di nome aziendale in NAYA Biosciences Inc. e inizierà a quotarsi con il nuovo simbolo 'NAYA' il 22 ottobre 2024. Questo cambiamento segue la recente fusione con NAYA Biosciences, completata il 14 ottobre. La nuova società combinata manterrà la propria attività redditizia nel settore della fertilità, espandendosi nel campo dell'oncologia e delle malattie autoimmuni.
Il CEO Steve Shum ha dichiarato che il cambiamento di nome e il nuovo simbolo di scambio riflettono meglio la loro strategia aziendale ampliata. L'azienda punta a combinare entrate scalabili e redditizie dall'attività di fertilità con il potenziale delle terapie innovative. Il loro modello hub-and-spoke è progettato per condividere risorse e talenti per accelerare lo sviluppo di sussidiarie snelle e agili.
INVO Bioscience ha anunciado un cambio de nombre corporativo a NAYA Biosciences Inc. y comenzará a cotizar con el nuevo símbolo 'NAYA' el 22 de octubre de 2024. Este cambio sigue a la reciente fusión con NAYA Biosciences, completada el 14 de octubre. La nueva compañía combinada mantendrá su negocio de fertilidad generador de ingresos, al mismo tiempo que se expandirá en el ámbito de la oncología y las enfermedades autoinmunes.
El CEO Steve Shum declaró que el cambio de nombre y el nuevo símbolo de cotización reflejan mejor su estrategia corporativa ampliada. La empresa tiene como objetivo combinar ingresos escalables y rentables del negocio de fertilidad con el potencial de terapias innovadoras. Su modelo de hub-and-spoke está diseñado para compartir recursos y talentos y acelerar el desarrollo de subsidiarias ágiles y eficientes.
INVO Bioscience는 기업명을 NAYA Biosciences Inc.로 변경한다고 발표하며, 2024년 10월 22일부터 새로운 심볼 'NAYA'로 거래를 시작할 예정입니다. 이 변화는 10월 14일에 완료된 NAYA Biosciences와의 최근 합병에 따른 것입니다. 새로 결합된 회사는 수익을 창출하는 생식 사업을 유지하면서 종양학 및 자가면역 질환으로 확장할 것입니다.
CEO 스티브 쉼은 이름 변경과 새로운 거래 기호가 그들의 확장된 기업 전략을 더 잘 반영한다고 밝혔습니다. 이 회사는 생식 사업에서의 확장 가능하고 수익성 있는 수익을 혁신적인 치료의 잠재력과 결합하는 것을 목표로 하고 있습니다. 그들의 허브-스포크 모델은 자원과 인재를 공유하기 위해 설계되어, 슬림하고 민첩한 자회사의 개발을 가속화합니다.
INVO Bioscience a annoncé un changement de nom d'entreprise en NAYA Biosciences Inc. et commencera à échanger sous le nouveau symbole 'NAYA' le 22 octobre 2024. Ce changement fait suite à la récente fusion avec NAYA Biosciences, achevée le 14 octobre. La nouvelle entreprise combinée continuera de générer des revenus grâce à son activité de fertilité tout en s'étendant au cancer et aux maladies auto-immunes.
Le PDG Steve Shum a déclaré que le changement de nom et le nouveau symbole de négociation reflètent mieux leur stratégie d'entreprise élargie. L'entreprise vise à combiner des revenus évolutifs et rentables provenant de l'activité de fertilité avec le potentiel de thérapies innovantes. Leur modèle hub-and-spoke est conçu pour partager des ressources et des talents afin d'accélérer le développement de filiales agiles et efficaces.
INVO Bioscience hat eine Unternehmensnamenänderung zu NAYA Biosciences Inc. angekündigt und wird ab dem 22. Oktober 2024 unter dem neuen Symbol 'NAYA' handeln. Diese Änderung folgt auf die kürzliche Fusion mit NAYA Biosciences, die am 14. Oktober abgeschlossen wurde. Das neu kombinierte Unternehmen wird sein umsatzgenerierendes Geschäft in der Fertilität beibehalten und sich gleichzeitig in den Bereich Onkologie und Autoimmunerkrankungen erweitern.
CEO Steve Shum erklärte, dass die Namensänderung und das neue Handelssymbol besser ihre erweiterte Unternehmensstrategie widerspiegeln. Das Unternehmen hat das Ziel, skalierbare, profitable Einnahmen aus dem Fertilitätsgeschäft mit dem Potenzial innovativer Therapeutika zu kombinieren. Ihr Hub-and-Spoke-Modell ist darauf ausgelegt, Ressourcen und Talente zu teilen, um die Entwicklung schlanker, agiler Tochtergesellschaften zu beschleunigen.
- Merger with NAYA Biosciences expands the company's portfolio into oncology and autoimmune diseases
- Maintaining revenue-generating fertility business while expanding into new therapeutic areas
- Hub-and-spoke model allows for shared resources and talent across subsidiaries
- None.
New Trading Symbol “NAYA” Effective Tuesday October 22, 2024
SARASOTA, Fla. and MIAMI, Oct. 21, 2024 (GLOBE NEWSWIRE) -- INVO Biosciences (Nasdaq: INVO), a company focused on expanding its portfolio of clinical and commercial-stage assets in fertility, oncology, and autoimmune diseases through the merger of INVO Biosciences and NAYA Biosciences, today confirmed it has changed its corporate name to NAYA Biosciences Inc. and will begin trading under the new symbol “NAYA” at the market open on Tuesday, October 22, 2024.
The CUSIP number for the Company's common stock will remain unchanged.
The name and symbol change follows the Company’s recent announcement on October 14th regarding the completion of its merger with NAYA Biosciences. The newly combined company will continue to operate the revenue-generating fertility business while expanding its focus on the development of first-in-class clinical-stage assets in oncology and autoimmune diseases.
“We believe the name change and new trading symbol better reflects our expanded corporate strategy,” commented Steve Shum, CEO of the combined company. “Combining scalable, profitable revenues from our fertility business with the upside of innovative therapeutics optimizes risk-return for investors. In addition, the hub-and-spoke model allows for shared resources and talent to accelerate the development of our lean, agile subsidiaries.”
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Investor & Media Contacts
INVO Bioscience
Steve Shum
Chief Executive Officer
sshum@invobio.com
Robert Blum
Lytham Partners
+1-602-889-9700
blum@lythampartners.com
NAYA Biosciences
Anna Baran-Djokovic
SVP, Investor Relations
+1-305-615-9162
anna@nayabiosciences.com
FAQ
When will INVO Bioscience start trading under the new symbol 'NAYA'?
What is the new corporate name for INVO Bioscience following the merger?
What new therapeutic areas will NAYA Biosciences focus on after the merger?
How does the merger affect INVO's existing fertility business?
